Cochrane review finds limited evidence for botulinum toxin in chronic migraine

Botulinum toxin may reduce the number of migraine days for people with chronic migraine by two per month, the first Cochrane review of the treatment has found. In a systematic review of 23 trials of botulinum toxin type A for chronic migraine (defined as more than 15 migraine days per month), the treatment was found ...

Already a member?

Login to keep reading.

© 2021 the limbic